INTRODUCTION: Orbital lesions are rare, but are likely to become symptomatic and can impact on patients' quality of life. Local control is often difficult to obtain, because of proximity to critical structures. CyberKnife stereotactic robotic radiotherapy could represent a viable treatment option. MATERIALS AND METHODS: Data on patients treated for intraorbital lesions from solid malignancies were retrospectively collected. All patients underwent treatment with CyberKnife system. We analyzed local control, response rate, symptoms control, progression-free survival and overall survival, acute and late toxicity. RESULTS: From January 2012 to May 2017, 20 treatments on 19 patients were performed, with dose ranging from 24 to 35 Gy in 1 to 5 fractions, prescribed at an average isodose line of 79.5% (range: 78-81). After a mean follow-up of 14.26 months (range: 0-58), overall response rate was 75%, with 2 and 4 patients presenting a partial and complete response, respectively. Mean time to best measured response was 15.16 months (range: 2-58). Thirteen patients were alive, with a local control rate of 79%. Mean time to local progression was 5 months (range: 3-7). Three patients reported improvement in symptoms after treatment. Mean planning target volume dose coverage was 97.2% (range: 93.5-99.7). Mean maximum dose (D max) to eye globe, optic nerve, optic chiasm, and lens was 2380.8 cGy (range: 290-3921), 1982.82 cGy (range: 777.3-2897.8), 713.14 cGy (range: 219.5-2273), and 867.9 cGy (range: 38-3118.5). Four patients presented acute toxicity. CONCLUSION: This current retrospective series demonstrated that CyberKnife robotic stereotactic radiotherapy is a feasible and tolerable approach for intraorbital lesions.

Efficacy and tolerability of cyberknife stereotactic robotic radiotherapy for primary or secondary orbital lesions: A single-center retrospective experience / Desideri, Isacco*; Francolini, Giulio; Carta, Giulio Alberto; Di Cataldo, Vanessa; Masi, Laura; Meattini, Icro; Bonomo, Pierluigi; Loi, Mauro; Greto, Daniela; Visani, Luca; Lo Russo, Monica; Grassi, Roberta; Teriaca, Maria Ausilia; Garlatti, Pietro; Nardi, Cosimo; Livi, Lorenzo. - In: TECHNOLOGY IN CANCER RESEARCH & TREATMENT. - ISSN 1533-0346. - ELETTRONICO. - 18:(2019), pp. 1533033818818561-1533033818818566. [10.1177/1533033818818561]

Efficacy and tolerability of cyberknife stereotactic robotic radiotherapy for primary or secondary orbital lesions: A single-center retrospective experience

Desideri, Isacco
;
Francolini, Giulio;Carta, Giulio Alberto;Di Cataldo, Vanessa;Meattini, Icro;Bonomo, Pierluigi;Loi, Mauro;Greto, Daniela;Visani, Luca;Lo Russo, Monica;Grassi, Roberta;Teriaca, Maria Ausilia;Garlatti, Pietro;Nardi, Cosimo;Livi, Lorenzo
2019

Abstract

INTRODUCTION: Orbital lesions are rare, but are likely to become symptomatic and can impact on patients' quality of life. Local control is often difficult to obtain, because of proximity to critical structures. CyberKnife stereotactic robotic radiotherapy could represent a viable treatment option. MATERIALS AND METHODS: Data on patients treated for intraorbital lesions from solid malignancies were retrospectively collected. All patients underwent treatment with CyberKnife system. We analyzed local control, response rate, symptoms control, progression-free survival and overall survival, acute and late toxicity. RESULTS: From January 2012 to May 2017, 20 treatments on 19 patients were performed, with dose ranging from 24 to 35 Gy in 1 to 5 fractions, prescribed at an average isodose line of 79.5% (range: 78-81). After a mean follow-up of 14.26 months (range: 0-58), overall response rate was 75%, with 2 and 4 patients presenting a partial and complete response, respectively. Mean time to best measured response was 15.16 months (range: 2-58). Thirteen patients were alive, with a local control rate of 79%. Mean time to local progression was 5 months (range: 3-7). Three patients reported improvement in symptoms after treatment. Mean planning target volume dose coverage was 97.2% (range: 93.5-99.7). Mean maximum dose (D max) to eye globe, optic nerve, optic chiasm, and lens was 2380.8 cGy (range: 290-3921), 1982.82 cGy (range: 777.3-2897.8), 713.14 cGy (range: 219.5-2273), and 867.9 cGy (range: 38-3118.5). Four patients presented acute toxicity. CONCLUSION: This current retrospective series demonstrated that CyberKnife robotic stereotactic radiotherapy is a feasible and tolerable approach for intraorbital lesions.
2019
18
1533033818818561
1533033818818566
Goal 4: Quality education
Desideri, Isacco*; Francolini, Giulio; Carta, Giulio Alberto; Di Cataldo, Vanessa; Masi, Laura; Meattini, Icro; Bonomo, Pierluigi; Loi, Mauro; Greto, Daniela; Visani, Luca; Lo Russo, Monica; Grassi, Roberta; Teriaca, Maria Ausilia; Garlatti, Pietro; Nardi, Cosimo; Livi, Lorenzo
File in questo prodotto:
File Dimensione Formato  
24 CyberKnife for orbital lesions - TCRT.pdf

accesso aperto

Descrizione: Articolo principale
Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 266.51 kB
Formato Adobe PDF
266.51 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1154058
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 0
social impact